Myostatin does not regulate cardiac hypertrophy or fibrosis

Ronald D. Cohn, Hsin Yueh Liang, Reena Shetty, Theodore Abraham, Kathryn Rae Wagner

Research output: Contribution to journalArticle

Abstract

Myostatin is a negative regulator of muscle growth. Loss of myostatin has been shown to cause increase in skeletal muscle size and improve skeletal muscle function and fibrosis in the dystrophin-deficient mdx muscular dystrophy mouse model. We evaluated whether lack of myostatin has an impact on cardiac muscle growth and fibrosis in vivo. Using genetically modified mice we assessed whether myostatin absence induces similar beneficial effects on cardiac function and fibrosis. Cardiac mass and ejection fraction were measured in wild-type, myostatin-null, mdx and double mutant mdx/myostatin-null mice by high resolution echocardiography. Heart mass, myocyte area and extent of cardiac fibrosis were determined post mortem. Myostatin-null mice do not demonstrate ventricular hypertrophy when compared to wild-type mice as shown by echocardiography (ventricular mass 0.69 ± 0.01 vs. 0.69 ± 0.018 g) and morphometric analyses including heart/body weight ratio (5.39 ± 0.45 vs. 5.62 ± 0.58 mg/g) and cardiomyocyte area 113.67 ± 1.5, 116.85 ± 1.9 μm2). Moreover, absence of myostatin does not attenuate cardiac fibrosis in the dystrophin-deficient mdx mouse (12.2% vs. 12%). The physiological role of myostatin in cardiac muscle appears significantly different than that in skeletal muscle as it does not induce cardiac hypertrophy and does not modulate cardiac fibrosis in mdx mice.

Original languageEnglish (US)
Pages (from-to)290-296
Number of pages7
JournalNeuromuscular Disorders
Volume17
Issue number4
DOIs
StatePublished - Apr 2007

Fingerprint

Myostatin
Cardiomegaly
Fibrosis
Inbred mdx Mouse
Dystrophin
Skeletal Muscle
Echocardiography
Myocardium
Muscular Dystrophies
Growth
Cardiac Myocytes
Muscle Cells
Hypertrophy
Body Weight

Keywords

  • Cardiomyopathy
  • Duchenne muscular dystrophy
  • Myostatin

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

Myostatin does not regulate cardiac hypertrophy or fibrosis. / Cohn, Ronald D.; Liang, Hsin Yueh; Shetty, Reena; Abraham, Theodore; Wagner, Kathryn Rae.

In: Neuromuscular Disorders, Vol. 17, No. 4, 04.2007, p. 290-296.

Research output: Contribution to journalArticle

Cohn, Ronald D. ; Liang, Hsin Yueh ; Shetty, Reena ; Abraham, Theodore ; Wagner, Kathryn Rae. / Myostatin does not regulate cardiac hypertrophy or fibrosis. In: Neuromuscular Disorders. 2007 ; Vol. 17, No. 4. pp. 290-296.
@article{47742b9afce7489ba2999d0b8b2f62b5,
title = "Myostatin does not regulate cardiac hypertrophy or fibrosis",
abstract = "Myostatin is a negative regulator of muscle growth. Loss of myostatin has been shown to cause increase in skeletal muscle size and improve skeletal muscle function and fibrosis in the dystrophin-deficient mdx muscular dystrophy mouse model. We evaluated whether lack of myostatin has an impact on cardiac muscle growth and fibrosis in vivo. Using genetically modified mice we assessed whether myostatin absence induces similar beneficial effects on cardiac function and fibrosis. Cardiac mass and ejection fraction were measured in wild-type, myostatin-null, mdx and double mutant mdx/myostatin-null mice by high resolution echocardiography. Heart mass, myocyte area and extent of cardiac fibrosis were determined post mortem. Myostatin-null mice do not demonstrate ventricular hypertrophy when compared to wild-type mice as shown by echocardiography (ventricular mass 0.69 ± 0.01 vs. 0.69 ± 0.018 g) and morphometric analyses including heart/body weight ratio (5.39 ± 0.45 vs. 5.62 ± 0.58 mg/g) and cardiomyocyte area 113.67 ± 1.5, 116.85 ± 1.9 μm2). Moreover, absence of myostatin does not attenuate cardiac fibrosis in the dystrophin-deficient mdx mouse (12.2{\%} vs. 12{\%}). The physiological role of myostatin in cardiac muscle appears significantly different than that in skeletal muscle as it does not induce cardiac hypertrophy and does not modulate cardiac fibrosis in mdx mice.",
keywords = "Cardiomyopathy, Duchenne muscular dystrophy, Myostatin",
author = "Cohn, {Ronald D.} and Liang, {Hsin Yueh} and Reena Shetty and Theodore Abraham and Wagner, {Kathryn Rae}",
year = "2007",
month = "4",
doi = "10.1016/j.nmd.2007.01.011",
language = "English (US)",
volume = "17",
pages = "290--296",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Myostatin does not regulate cardiac hypertrophy or fibrosis

AU - Cohn, Ronald D.

AU - Liang, Hsin Yueh

AU - Shetty, Reena

AU - Abraham, Theodore

AU - Wagner, Kathryn Rae

PY - 2007/4

Y1 - 2007/4

N2 - Myostatin is a negative regulator of muscle growth. Loss of myostatin has been shown to cause increase in skeletal muscle size and improve skeletal muscle function and fibrosis in the dystrophin-deficient mdx muscular dystrophy mouse model. We evaluated whether lack of myostatin has an impact on cardiac muscle growth and fibrosis in vivo. Using genetically modified mice we assessed whether myostatin absence induces similar beneficial effects on cardiac function and fibrosis. Cardiac mass and ejection fraction were measured in wild-type, myostatin-null, mdx and double mutant mdx/myostatin-null mice by high resolution echocardiography. Heart mass, myocyte area and extent of cardiac fibrosis were determined post mortem. Myostatin-null mice do not demonstrate ventricular hypertrophy when compared to wild-type mice as shown by echocardiography (ventricular mass 0.69 ± 0.01 vs. 0.69 ± 0.018 g) and morphometric analyses including heart/body weight ratio (5.39 ± 0.45 vs. 5.62 ± 0.58 mg/g) and cardiomyocyte area 113.67 ± 1.5, 116.85 ± 1.9 μm2). Moreover, absence of myostatin does not attenuate cardiac fibrosis in the dystrophin-deficient mdx mouse (12.2% vs. 12%). The physiological role of myostatin in cardiac muscle appears significantly different than that in skeletal muscle as it does not induce cardiac hypertrophy and does not modulate cardiac fibrosis in mdx mice.

AB - Myostatin is a negative regulator of muscle growth. Loss of myostatin has been shown to cause increase in skeletal muscle size and improve skeletal muscle function and fibrosis in the dystrophin-deficient mdx muscular dystrophy mouse model. We evaluated whether lack of myostatin has an impact on cardiac muscle growth and fibrosis in vivo. Using genetically modified mice we assessed whether myostatin absence induces similar beneficial effects on cardiac function and fibrosis. Cardiac mass and ejection fraction were measured in wild-type, myostatin-null, mdx and double mutant mdx/myostatin-null mice by high resolution echocardiography. Heart mass, myocyte area and extent of cardiac fibrosis were determined post mortem. Myostatin-null mice do not demonstrate ventricular hypertrophy when compared to wild-type mice as shown by echocardiography (ventricular mass 0.69 ± 0.01 vs. 0.69 ± 0.018 g) and morphometric analyses including heart/body weight ratio (5.39 ± 0.45 vs. 5.62 ± 0.58 mg/g) and cardiomyocyte area 113.67 ± 1.5, 116.85 ± 1.9 μm2). Moreover, absence of myostatin does not attenuate cardiac fibrosis in the dystrophin-deficient mdx mouse (12.2% vs. 12%). The physiological role of myostatin in cardiac muscle appears significantly different than that in skeletal muscle as it does not induce cardiac hypertrophy and does not modulate cardiac fibrosis in mdx mice.

KW - Cardiomyopathy

KW - Duchenne muscular dystrophy

KW - Myostatin

UR - http://www.scopus.com/inward/record.url?scp=34047101435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047101435&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2007.01.011

DO - 10.1016/j.nmd.2007.01.011

M3 - Article

VL - 17

SP - 290

EP - 296

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - 4

ER -